To determine whether tobramycin, administered in the gut, permeates from the gut into the blood and is subsequently excreted into the urine.
ID
Source
Brief title
Condition
- Ancillary infectious topics
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
concentrations of tobramycin in blood
excretion of tobramycin in urine
Secondary outcome
renal function
SOFA score
APACHE score
Background summary
For the prevention of pathological colonisation of the digestive tract and
subsequent infections critically, ill patients are treated with antibiotics in
the gastrointestinal tract. Normally, these antibiotics remain in the gut.
During critical illness, gut permeability may be increased. As a result, the
enterally administered antibiotics might permeate from the gut to the blood.
Study objective
To determine whether tobramycin, administered in the gut, permeates from the
gut into the blood and is subsequently excreted into the urine.
Study design
observational cohort pilot study
Study burden and risks
no burden or risks
Oosterpark 9
1090 HM Amsterdam
Nederland
Oosterpark 9
1090 HM Amsterdam
Nederland
Listed location countries
Age
Inclusion criteria
Critically ill patients acutely admitted to the intensive care patients, treated with selective decontamination of the digestive tract for at least 24 hours.
Exclusion criteria
Intravenous use of tobramycin or gentamycin
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL13783.067.06 |